Individualisation of treatment regimens and goals is recommended for managing familial dyslipidaemias

Familial dyslipidaemias usually result from a genetic abnormality combined with a secondary factor, such as lifestyle, medication use or disease, and are an important cause of morbidity and mortality. Lifestyle modifications and/or certain dietary supplements should be the first management option, but are usually of limited benefit, and pharmacotherapy with one or more lipid-lowering agents is usually required. Management is currently based on the predominant lipid abnormalities. Pharmacotherapy and therapeutic goals must be individualised for each patient